Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Abstract Background At present, immune checkpoint inhibitors, such as pembrolizumab, are widely used in the therapy of advanced non-resectable melanoma, as they induce more durable responses than other available treatments. However, the overall response rate does not exceed 50% and, considering the...

Full description

Bibliographic Details
Main Authors: Neta Tsur, Yuri Kogan, Evgenia Avizov-Khodak, Désirée Vaeth, Nils Vogler, Jochen Utikal, Michal Lotem, Zvia Agur
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Journal of Translational Medicine
Subjects:
Immunotherapy
Immune checkpoint blocker
PD-1
Pembrolizumab
Prediction algorithm
Effector CD8+ T Lymphocytes
Online Access:http://link.springer.com/article/10.1186/s12967-019-2081-2

Internet

http://link.springer.com/article/10.1186/s12967-019-2081-2

Similar Items